Arabic Arabic English English French French German German
dark

With Anti-CD47 Cancer Drugs Trending, Arch Takes in $105 Million for its Antibody

The race is on in the CD47 field, and Brisbane-based player Arch Oncology just upped the bet with a $105 million Series C raise.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

2021 Jones Award: Edward J. Smith

Next Post

Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease

Related Posts
Total
0
Share